祥生医疗 - Financials

祥生医疗 — Financial Statements

Annual Quarterly

5 10 All

Income Statement

Balance Sheet

Cash Flow

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020	FY 2019Dec 31, 2019	FY 2018Dec 31, 2018	FY 2017Dec 31, 2017	FY 2016Dec 31, 2016
+Revenue	469.0M	484.0M	381.0M	398.0M	333.0M	370.0M	327.0M	272.0M	167.0M
Revenue Growth %	-3.1%	27.0%	-4.3%	19.5%	-10.0%	13.1%	20.2%	62.9%	--
Total Revenue	469.0M	484.0M	381.0M	398.0M	333.0M	370.0M	327.0M	272.0M	167.0M
Cost Of Revenue	192.0M	203.0M	155.0M	174.0M	138.0M	145.0M	127.0M	110.0M	71.0M
+Gross Profit	277.0M	281.0M	226.0M	224.0M	195.0M	225.0M	200.0M	162.0M	96.0M
Gross Margin %	59.1%	58.1%	59.3%	56.3%	58.6%	60.8%	61.2%	59.6%	57.5%
Total Operating Cost	334.0M	354.0M	295.0M	338.0M	264.0M	271.0M	239.0M	213.0M	141.0M
Selling Expenses	55.0M	49.3M	50.3M	49.8M	38.4M	50.4M	45.5M	36.4M	29.1M
Admin Expenses	37.6M	34.9M	33.3M	28.2M	20.1M	21.4M	21.7M	23.3M	12.0M
Rd Expenses	79.6M	77.1M	77.9M	72.3M	55.6M	52.0M	41.3M	33.1M	28.3M
Finance Expenses	-40.9M	-23.7M	-28.2M	3.9M	8.2M	-3.6M	-2.7M	5.4M	-3.3M
+Operating Income	157.0M	162.0M	115.0M	125.0M	109.0M	116.0M	107.0M	71.5M	26.4M
Operating Margin %	33.5%	33.5%	30.2%	31.4%	32.7%	31.4%	32.7%	26.3%	15.8%
Non Operating Income	94,500	406,100	67,800	640,200	4.4M	2.0M	512,400	3.0M	7.2M
Non Operating Expenses	548,400	435,000	69,100	1.1M	1.7M	58,100	145,100	537,400	61,900
Investment Income	6.1M	10.6M	14.0M	17.1M	27.2M	2.1M	--	--	--
Fair Value Change Income	171,000	2.9M	-1.4M	425,300	--	--	--	--	--
Asset Disposal Income	4.6M	3.0M	-502,800	30.3M	12,300	-2,300	--	--	-11,000
Asset Impairment Loss	4.6M	5.5M	4.3M	4.7M	-361,500	303,300	2.1M	836,700	1.7M
Other Income	12.0M	15.4M	16.7M	17.3M	12.9M	15.2M	18.8M	12.7M	--
Income Before Tax	157.0M	162.0M	115.0M	125.0M	112.0M	118.0M	107.0M	74.0M	33.5M
Income Tax	16.3M	15.7M	9.3M	12.1M	11.9M	12.8M	12.0M	10.0M	3.0M
+Net Income	141.0M	146.0M	106.0M	112.0M	99.6M	105.0M	95.1M	64.0M	30.5M
Net Margin %	30.1%	30.2%	27.8%	28.1%	29.9%	28.4%	29.1%	23.5%	18.2%
Net Income Attributable	141.0M	146.0M	106.0M	112.0M	99.6M	105.0M	95.1M	64.0M	30.5M
Eps Basic	1.26	1.33	0.94	1.00	1.25	1.70	1.58	1.07	0.51
Eps Diluted	1.26	1.33	0.94	1.00	1.25	1.70	1.58	1.07	0.51

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020	FY 2019Dec 31, 2019	FY 2018Dec 31, 2018	FY 2017Dec 31, 2017	FY 2016Dec 31, 2016
Cash And Equivalents	986.0M	689.0M	446.0M	446.0M	302.0M	1.1B	135.0M	84.4M	53.4M
Trading Financial Assets	115.0M	341.0M	581.0M	580.0M	745.0M	--	--	--	--
Accounts Receivable	162.0M	155.0M	93.5M	136.0M	126.0M	107.0M	52.0M	42.3M	25.0M
Notes And Accounts Receivable	162.0M	155.0M	93.5M	136.0M	126.0M	107.0M	52.0M	42.3M	25.0M
Prepayments	3.5M	5.2M	2.4M	2.2M	3.8M	1.8M	1.8M	1.1M	1.4M
Inventory	126.0M	136.0M	197.0M	99.5M	84.1M	58.3M	59.8M	46.8M	40.4M
Total Current Assets	1.4B	1.3B	1.3B	1.3B	1.3B	1.2B	268.0M	185.0M	125.0M
Fixed Assets	--	79.6M	79.2M	84.5M	27.9M	21.3M	22.1M	21.7M	21.3M
Fixed Assets Total	76.3M	79.6M	79.2M	84.5M	27.9M	21.3M	22.1M	21.7M	21.3M
Construction In Progress	--	55.6M	52.3M	8.7M	18.6M	1.3M	--	--	--
Construction In Progress Total	76.3M	55.6M	52.3M	8.7M	18.6M	1.3M	--	--	--
Intangible Assets	20.4M	21.1M	22.1M	22.5M	23.8M	24.3M	25.0M	25.2M	2.3M
Long Term Deferred Expenses	881,000	690,300	3,000	133,800	372,100	611,700	871,700	1.1M	125,200
Total Non Current Assets	192.0M	181.0M	175.0M	128.0M	78.9M	55.4M	55.6M	53.1M	28.1M
Total Assets	1.6B	1.5B	1.5B	1.4B	1.4B	1.3B	324.0M	238.0M	153.0M
Accounts Payable	81.0M	84.6M	128.0M	80.3M	73.2M	53.3M	32.3M	35.0M	25.0M
Advance Receipts	--	--	--	--	--	1.3M	3.9M	5.8M	13.8M
Contract Liabilities	30.7M	16.0M	23.0M	25.2M	26.8M	--	--	--	--
Total Current Liabilities	167.0M	138.0M	188.0M	140.0M	129.0M	89.9M	84.0M	72.8M	72.4M
Total Non Current Liabilities	9.6M	15.0M	11.9M	12.8M	27.7M	29.8M	30.4M	20.8M	4.3M
Total Liabilities	176.0M	153.0M	200.0M	152.0M	157.0M	120.0M	114.0M	93.6M	76.7M
Paid In Capital	112.0M	112.0M	112.0M	80.0M	80.0M	80.0M	60.0M	60.0M	50.0M
Capital Reserve	904.0M	905.0M	908.0M	938.0M	933.0M	931.0M	31.5M	30.9M	286,200
Surplus Reserve	56.1M	56.1M	52.3M	40.0M	32.9M	23.5M	15.3M	2.2M	22.3M
Retained Earnings	357.0M	306.0M	242.0M	188.0M	147.0M	137.0M	103.0M	51.1M	4.0M
Equity Attributable	1.4B	1.4B	1.3B	1.2B	1.2B	1.2B	209.0M	144.0M	76.3M
Total Equity	1.4B	1.4B	1.3B	1.2B	1.2B	1.2B	209.0M	144.0M	76.3M

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020	FY 2019Dec 31, 2019	FY 2018Dec 31, 2018	FY 2017Dec 31, 2017	FY 2016Dec 31, 2016
Cash From Sales	483.0M	427.0M	447.0M	360.0M	355.0M	341.0M	329.0M	253.0M	172.0M
Tax Refunds Received	30.7M	30.2M	37.5M	37.9M	25.3M	48.8M	38.6M	30.1M	16.4M
Total Operating Cash Inflow	546.0M	482.0M	497.0M	408.0M	390.0M	399.0M	382.0M	291.0M	193.0M
Cash Paid For Goods	201.0M	189.0M	237.0M	192.0M	165.0M	156.0M	156.0M	116.0M	66.2M
Cash Paid To Employees	132.0M	130.0M	121.0M	107.0M	83.0M	88.1M	75.7M	56.3M	44.7M
Taxes Paid	28.3M	30.7M	31.0M	23.6M	25.7M	35.1M	39.8M	22.0M	12.1M
Total Operating Cash Outflow	405.0M	396.0M	433.0M	368.0M	308.0M	319.0M	310.0M	229.0M	151.0M
Operating Cash Flow	141.0M	85.9M	63.7M	40.0M	82.4M	79.8M	71.4M	62.2M	42.1M
Total Investing Cash Inflow	3.1B	2.6B	2.3B	2.7B	3.6B	931.0M	--	--	--
Total Investing Cash Outflow	2.6B	2.8B	2.3B	2.6B	4.4B	936.0M	5.8M	14.2M	7.5M
Investing Cash Flow	556.0M	-241.0M	-45.4M	164.0M	-749.0M	-5.3M	-5.8M	-14.2M	-7.5M
Dividends And Interest Paid	89.5M	78.5M	40.0M	64.0M	80.0M	81.4M	19.0M	13.1M	30.0M
Total Financing Cash Inflow	--	--	2.0M	--	--	940.0M	--	5.5M	9.8M
Total Financing Cash Outflow	93.8M	89.5M	40.9M	64.6M	91.2M	90.6M	19.0M	18.6M	39.8M
Financing Cash Flow	-93.8M	-89.5M	-38.9M	-64.6M	-91.2M	849.0M	-19.0M	-13.1M	-30.0M
Net Change In Cash	615.0M	-235.0M	990,400	136.0M	-761.0M	928.0M	51.0M	30.9M	8.1M
Ending Cash Balance	819.0M	204.0M	439.0M	438.0M	302.0M	1.1B	135.0M	84.4M	53.4M
Capex	8.9M	34.0M	52.2M	39.2M	30.9M	7.8M	5.8M	14.2M	7.5M